The lack of viable antibiotics has urged researchers to think of new approaches to treat deadly bacterial infections. This editorial discusses the progress so far, and the future applications, of strategies involving predatory bacteria.
Antivirulence agents represent an attractive alternative to antibiotics. Here, the authors discuss the advantages, and the gaps in antivirulence therapy.
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.
Prions are transmissible agents composed of aggregates of misfolded cellular prion protein (PrP) that cause fatal neurodegenerative diseases. Here the authors looks into what genomics can tell us about prion diseases, and gives a perspective on future needs.
In this editorial the authors offer a perspective about issues surrounding the implementation of molecular antibiograms in the diagnostic workflow.
The recurring resistance of the malaria parasite to many drugs compels the design of innovative chemical entities in antimalarial research. In light of this, the authors discuss thiaheterocyclic hHDAC6 inhibitors as potentially powerful novel antimalarials.
In this systematic review from Future Microbiology the author assesses data of Phase I–III trials including malaria-naive adults and adults, children and infants from malaria endemic settings in sub-Saharan Africa.
This Editorial discusses a Health Economics and Outcomes Research (HEOR) approach to use a formal comparative effectiveness analysis and a network meta-analysis for both first- and second-line ART regimens for adults, adolescents and children.
Given the ability of the microbiota to instruct the immune system and control the inflammatory response, the authors discuss the potential of targeting the microbiota to improve the immune recovery and dampen inflammation during HIV infection.
In this editorial the authors discuss how targeting the human TREX complex could prevent herpesvirus replication, highlighting their own work targeting herpesvirus lytic replication through inhibition of the hTREX complex.